The Next Frontier of Disease Monitoring and Management?

How home-based telemedicine could be transformational for patients with AMD.

By Judy E. Kim, MD

Connected health, also known as technology-enabled care (TEC), is a broad term that encompasses concepts such as telehealth, telecare, telemedicine, and cloud-based home monitoring platforms. TEC innovations are evolving at lightning speed. They aim to disrupt traditional care models, improve quality of care and patient outcomes, and provide a conduit for personalized medicine.


• Anti-VEGF therapy revolutionized the treatment of patients with wet AMD, but there is still a long way to go to achieve optimal long-term VA outcomes.
• A substantial opportunity exists to optimize these long-term outcomes through earlier detection by having those at risk for disease progression use home monitoring technology.
• Technology-enabled home monitoring has the potential to personalize disease management and improve the patient journey.

The introductions of glucometers and blood pressure monitors decades ago seem almost primitive when compared with the new Apple Watch Series 4 (Apple). The watch, which has received two US FDA clearances for use as a medical device, allows wearers to obtain electrocardiogram readings they can share with their physicians. It can also detect hard falls. When one is detected, it can then initiate an emergency call, if needed.

Technology is making meaningful changes in how medical specialists monitor and manage disease. For retina specialists, embracing this future-forward trend toward personalized connected medicine could mean a transformational shift in how we treat patients with a multitude of diseases, including those diagnosed with wet age-related macular degeneration (AMD).


Without question, the introduction of anti-VEGF therapy in 2004 revolutionized the treatment of wet AMD; however, there is still a long way to go to achieve optimal long-term VA outcomes, as real-world concerns pose significant barriers.

Both clinical trials1-3 and real-world studies4,5 have shown that more than 95% of patients started on anti-VEGF therapy can maintain VA within 3 lines of baseline VA. These studies confirm that prompt recognition of conversion to wet AMD and subsequent initiation of treatment are essential for good long-term vision outcomes. Furthermore, studies consistently demonstrate that better VA at the time of diagnosis and treatment initiation is the strongest predictor of better long-term VA.

Despite these findings, too many patients are diagnosed with baseline VA worse than 20/40.6 Significant opportunity exists to optimize long-term outcomes through earlier detection using technology-enabled home monitoring for those at risk of disease progression.


AMD, the leading cause of blindness for individuals older than 50 years, is projected to affect 25 million people by 2020 and as many as 38 million people by 2040.7 This is not surprising, given that, by 2030, one in five people in the United States will be of retirement age.8

As patients are getting older, the number of ophthalmologists needed to fulfill the demands of their care may be insufficient. A recent report projected a shortage of 6,180 ophthalmologists by 2025.9 Furthermore, it is forecast that in the coming years there will be fewer retina specialists relative to the increasing number of patients. TEC that efficiently and accurately complements our office-based care will allow us to manage this increased patient load while optimizing long-term VA outcomes of our patients with AMD.

A 2018 poll from the Associated Press-NORC Center for Public Affairs Research found that nine in 10 respondents aged ≥ 40 years would be comfortable using at least one form of telemedicine.10 Evidence also suggests that patients with AMD are receptive to using technologies that allow them to participate in the management of their disease.11 The willingness of patients to embrace technology is especially meaningful in AMD, where studies have noted a correlation between loss of central vision and decreased independence, increases in depression and risk of fall, and decline in cognitive function.


The concept of home monitoring for patients with AMD is not new—the Amsler grid is a proven, time-tested tool that is easy for patients to use. However, significant limitations of the Amsler grid include poor compliance, low or variable sensitivity, and lack of automated transfer of abnormal results to physicians. These limitations raise questions about the Amsler grid’s utility for patients at risk for conversion to wet AMD.12

TEC can help address these limitations. Two TEC options are currently on the forefront of home monitoring in AMD: the mVT app (myVision Track; Vital Art and Science) and the ForeseeHome AMD Monitoring Program (Notal Vision).

The mVT App

This FDA-cleared application is available for use on Apple and Android smartphones. The mVT app is available by prescription, costs $19.95 per month, and relies on shape discrimination hyperacuity testing. Patients can use the app to monitor themselves for any significant vision changes associated with maculopathy, including AMD. Prescribing physicians are alerted via their choice of portal (email or phone) when changes are detected. The recommendation for testing is twice per week, although the app does not ensure regular use (ie, accountability for compliance rests with the user).

ForeseeHome AMD Monitoring Program

This service, available by physician order, uses preferential hyperacuity perimetry, an application of Vernier acuity, to detect minute differences in the relative spatial localization of two or more objects. The technology has been validated in a multicenter, prospective, randomized clinical trial sponsored by the National Institutes of Health,13 which led to its being covered by Medicare and most private insurance with no cost for most patients.

In the AREDS2 HOME Study of 1,520 patients with intermediate dry AMD, 94% of patients who used the ForeseeHome device at least twice weekly maintained 20/40 or better VA at the time choroidal neovascularization was detected, compared with 62% in the standard-of-care arm. Moreover, those in the standard-of-care arm lost more letters (-9 letters) from baseline, on average, than those in the ForeseeHome group (-3 letters) at the time of choroidal neovascularization detection.13

When the ForseeHome device detects threshold changes in a patient’s test score, an alert is sent to a designated contact, and an appointment is made for the patient to see a physician. Additionally, monthly reports are emailed to the physician’s practice, and test results are available any time via the Notal Vision portal. Alerts can also be sent to patients with the physician’s written consent.

ForeseeHome also addresses the need for compliance, as it tracks the frequency of usage. To encourage compliance, the Data Monitoring Center contacts the patient if no results are received for 7 consecutive days.


Once a patient is diagnosed with wet AMD, many retina specialists employ a treat-and-extend or as-needed regimen with anti-VEGF injections in an attempt to tailor the treatment to the patient’s response and reduce treatment burden. Most retina specialists incorporate findings from OCT, VA, and clinical examination when assessing treatment response and making treatment decisions.

Although maintenance of disease-free intervals between treatments is key to optimal wet AMD management and better long-term visual outcomes, we currently do not have a good biomarker to accurately determine disease-free intervals for every patient. Furthermore, real-world visual outcomes have not yielded the results observed in clinical trials; this is thought to be due to unwanted fluid in the retina with undertreatment.

What if we could truly personalize retinal fluid management while reducing the burden of frequent follow-up visits? What if we could minimize the days with fluid in the retina, gain between-visit knowledge regarding the disease or the treatment response and maintain VA over time? What if patients could image their own eyes on a regular basis with an at-home OCT device to help determine when they should return to their physician for follow-up? What if those OCT images could be interpreted rapidly and accurately using artificial intelligence?

An at-home OCT monitoring program would complement in-office OCT and allow patients to play a larger role in the management of their disease, resulting in more timely and personalized treatment intervals. This could potentially translate to better visual outcomes while reducing treatment burden. The Notal OCT Analyzer (NOA; Notal Vision), currently in development, performs fully automated detection of lesion activity—defined as the presence of fluid in the various tissue compartments when applied to a macular volume scan. In a published clinical trial, the performance of NOA, which uses a machine-learning algorithm, was comparable in sensitivity and specificity to that of retina specialists in detecting abnormal OCTs selected from an image repository at a tertiary center.14

Compact Imaging is developing miniaturized OCT devices and home retinal monitoring based on the company’s proprietary MRO (Multiple Reference OCT) technology, and the company recently signed a collaboration agreement with Novartis Pharma stating that Novartis will fund its development of a low-cost home-based monitor to detect disease progression in advanced cases of AMD and diabetic retinopathy.15 According to Compact Imaging, the technical feasibility of MRO has already been demonstrated, achieving results similar to clinical OCT in a study measuring retinal thickness in healthy eyes. Clinical trials of a prototype system for patients with active AMD or DME are expected to begin in the second half of 2019.


The time has come to employ modern home monitoring options in order to better personalize disease management and improve our patients’ journeys. The future of teleophthalmology is potentially transformative in patient management. Let’s make sure we provide our AMD patients with the best chance at maintaining optimal VA long term.

1. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J MedM. 2006;355(14):1432-1444.

2. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J MedM. 2006;355(14):1419-1431.

3. Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. OphthalmologyM. 2012;119(12):2537-2548.

4. Lee AY, Lee CS, Butt T, et al; UK AMD EMR Users Group. UK AMD EMR Users group report V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. Br J OphthalmolM. 2015;99(8):1045-1050.

5. Gillies MC, Campain A, Barthelmes D, et al; Fight Retinal Blindness Study Group. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. OphthalmologyM. 2015;122(9):1837-1845.

6. Ho AC, Albini TA, Brown DM, Boyer DS, Regillo CD, Heier JS. The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good. JAMA OphthalmolM. 2017;135(3):268-273.

7. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob HealthM. 2014;2:e106-e116.

8. United States Census Bureau. Older people projected to outnumber children for first time in U.S. history [press release]. March 13, 2018. Accessed September 26, 2018.

9. National and regional projections of supply and demand for surgical specialty practitioners: 2013-2025. US Department of Health and Human Services and Health Resources and Services Administration. December 2016. Accessed October 10, 2018.

10. Many older Americans open to using technology to increase access to care. Long-Term Care Poll. May 20, 2018. Accessed November 2, 2018.

11. Schwartz R, Loewenstein A. Early detection of age related macular degeneration: current status. Int J Retina VitreousM. 2015;1:20.

12. Vazquez NP, Knox PC. Assessment of visual distortions in age-related macular degeneration: emergence of new approaches. Br Ir Orthopt JM. 2015;12:9-15.

13. Chew EY, Clemons TE, Bressler SB, et al; the AREDS2-HOME Study Research Group. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the eye (HOME) study. OphthalmologyM. 2014;121(2):535-544.

14. Chakravarthy U, Goldenberg D, Young G, et al. Automated identification of lesion activity in neovascular age-related macular degeneration. OphthalmologyM. 2016;123(8):1731-1736.

15. Compact Imaging collaborates with Global Pharma to accelerate development of home monitor for age-related macular degeneration and diabetic retinopathy [press release]. Compact Imaging. October 25, 2018. Accessed November 20, 2018.

Judy E. Kim, MD
• Professor of Ophthalmology, Vitreoretinal Diseases and Surgery, Medical College of Wisconsin, Milwaukee
• Financial disclosure: Consultant (Genentech, Notal Vision)


Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Scott Krzywonos

Janet Burk

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.